Health
Rutgers leading coronavirus therapeutic clinical trial – EurekAlert
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with…
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections.
The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine…
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business14 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?